SVR Rates of HCV-infected Population Under PEG-IFN-α/R Treatment in Northwest China

Virology Journal - United Kingdom
doi 10.1186/s12985-017-0708-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV Co-Infected Patients: Implications for Treatment Outcomes

Journal of Hepatology
Hepatology
2010English

Changes in Immune Activation in the T Cell Compartments of HIV HCV Coinfected Patients During PEG IFN RBV Treatment

Retrovirology
VirologyInfectious Diseases
2012English

Therapeutic Response to Peg-Ifn-Alpha-2b and Ribavirin in HIV/HCV Co-Infected African-American and Caucasian Patients as a Function of HCV Viral Kinetics and Interferon Pharmacodynamics

AIDS
Infectious DiseasesAllergyImmunology
2009English

Treatment of Chronic HCV Infection With DAAs in Rio De Janeiro/Brazil: SVR Rates and Baseline Resistance Analyses in NS5A and NS5B Genes

PLoS ONE
Multidisciplinary
2019English

HCV Eradication With New IFN Free Treatment Improves Metabolic Profile in HCV-related Liver Transplant Recipients

Liver Transplantation
HepatologyTransplantationSurgery
2018English

Hepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell Counts

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2009English

Spatial Pattern and Population Structure of Artemisia Ordosica Shrub in a Desert Grassland Under Enclosure, Northwest China

International Journal of Environmental Research and Public Health
MutagenesisPublic HealthEnvironmentalHealthToxicologyOccupational HealthPollution
2018English

Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers

HIV Clinical Trials
2009English

The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-Ifn-Α 2a in HBeAgpositive CHB Patients

Infection International
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy